HealthTech Company Rapid Nutrition Releases 2024 Results,
Positioning for Future Growth
London, United Kingdom – 4 April 2025 - Rapid Nutrition PLC (Euronext Growth: ALRPD) releases its fiscal year 2024 results. An innovative HealthTech leader dedicated to advancing global wellness, proudly announces its 2024 annual results.
Financial Highlights
- Inventory Growth Reflects Product Demand and Expansion
Inventory increased significantly by 93% (from $173,015 in 2023 to $334,298 in 2024), demonstrating higher product demand and readiness to support new market expansion, particularly in key regions like China and APAC.
- Significant Reduction in Administrative Expenses
Administrative expenses decreased by 24% (from $2,285,011 in 2023 to $1,728,597 in 2024), showing strong cost discipline and efforts to optimize operational efficiency.
- Strategic Restructuring and Revenue Momentum
Although turnover decreased, this was due to the planned restructuring of the SystemLS brand under the new King Kong partnership. The new website, completed in July 2024, already delivered additional revenue outside the reporting period, signaling early success and potential for sustained growth in FY2025.
- Improved Receivables and Liquidity Indicators
Trade and other receivables increased significantly by 175% (from $162,719 in 2023 to $448,691 in 2024), reflecting stronger collection cycles and anticipated future revenue. Combined with robust inventory, this ensures the company is well-positioned for operational continuity.
- Strong Improvement in Earnings Per Share
The Company reported basic and diluted earnings per share of 0.0383 in 2024, a substantial increase compared to 0.0011 in 2023, showing a notable improvement in earnings compared to the previous year.
The company's full financial report, including a comprehensive year-in-review and management report, is now available on its website.
About Rapid Nutrition
Rapid Nutrition is a global HealthTech company dedicated to advancing wellness through evidence-based, personalized nutrition solutions. Leveraging advanced technologies, AI, and scientific research, the company is committed to optimizing nutrition, improving health outcomes, and fostering sustainable, healthier lifestyles worldwide.
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).